# QL1706 Combined With Chemotherapy in the Treatment of Immune-mediated NSCLC

> **NCT07330596** · PHASE2 · RECRUITING · sponsor: **Anhui Provincial Cancer Hospital** · enrollment: 96 (estimated)

## Conditions studied

- NSCLC (Advanced Non-small Cell Lung Cancer)

## Interventions

- **DRUG:** QL1706 combined with Chemotherapy
- **DRUG:** Chemotherapy

## Key facts

- **NCT ID:** NCT07330596
- **Lead sponsor:** Anhui Provincial Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-30
- **Primary completion:** 2028-01-28
- **Final completion:** 2028-02-28
- **Target enrollment:** 96 (ESTIMATED)
- **Last updated:** 2026-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07330596

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07330596, "QL1706 Combined With Chemotherapy in the Treatment of Immune-mediated NSCLC". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07330596. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*